Advertisement

Evidence-Based Versus Evidence-Biased Medicine in Geriatric Cardiology: From Trials to Real World

  • Matteo MonamiEmail author
  • Mauro Di Bari
Chapter

Abstract

Elderly people are now the most rapidly growing part of the patient population worldwide, thanks to more focus on primary prevention of diseases and improvements in healthcare for the younger ill patient. Aging is often accompanied by chronic (multiple) diseases, comorbidity, disability, frailty, and social isolation. As a consequence, elderly persons are more likely to receive a high number of drugs; this phenomenon is called “polypharmacy” and is a problem affecting advanced decades and may lead to an increased risk of inappropriate drug use, underuse of effective treatments, medication errors, poor adherence, drug–drug and drug–disease interactions, and, most importantly, adverse drug reactions [1]. Moreover, the lack of well-designed clinical studies recruiting elderly limits the availability of evidence-based information on the effect of drugs on clinically relevant outcomes such as functional and cognitive decline, quality of life, adverse events, and mortality. This is a real problem for the majority of chronic conditions, particularly for cardiac diseases, which are predominant in elderly persons.

Keywords

Chronic Heart Failure Randomize Clinical Trial Elderly Person Inappropriate Drug Drug Regulatory Agency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Nobili A, Garattini S, Mannucci PM. Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. J Comorbidity. 2011;1:28–44.CrossRefGoogle Scholar
  2. 2.
    US Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Guideline for the study of drugs likely to be used in the elderly. November 1989. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072048.pdf. Accessed 30 Jan 2013.
  3. 3.
    International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Studies in support of special populations: geriatrics E7. June 1993. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E7/Step4/E7_Guideline.pdf. Accessed 30 Jan 2013.
  4. 4.
    Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007;297:1233–40.CrossRefPubMedGoogle Scholar
  5. 5.
    Cherubini A, Del Signore S, Ouslander J, Semla T, Michel JP. Fighting against age discrimination in clinical trials. J Am Geriatr Soc. 2010;58:1791–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011;171:550–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Crome P, Lally F, Cherubini A, et al. Exclusion of older people from clinical trials: professional views from nine European countries participating in the PREDICT study. Drugs Aging. 2011;28:667–77.CrossRefPubMedGoogle Scholar
  8. 8.
    PREDICT Charter for older people in clinical trials. http://www.predicteu.org/PREDICT_Charter/predict_charter.html. Accessed 30 Jan 2013.
  9. 9.
    Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Committee for Practice Guide- lines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388–442.CrossRefPubMedGoogle Scholar
  10. 10.
    McMurray JJ, Adamopoulos S, Anker SD, ESC Committee for Practice Guidelines, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.CrossRefPubMedGoogle Scholar
  11. 11.
    Evans JG. Evidence-based and evidence-biased medicine. Age Ageing. 1995;24:461–3.CrossRefPubMedGoogle Scholar
  12. 12.
    Bernabei R, Caputi A, Di Cioccio L, et al. Need for redesigning pharmacologic research in older individuals. A position statement of the Geriatric Working Group of the Agenzia Italiana del Farmaco (AIFA). J Gerontol A Biol Sci Med Sci. 2011;66:66–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.DaibetologyAzienda Ospedaliero-Universitaria CareggiFlorenceItaly
  2. 2.Division of Geriatric Cardiolog and Medicine, Research Unit of Medicine of Ageing, Department of Clinical and Experimental MedicineAzienda Ospedaliero-Universitaria CareggiFlorenceItaly

Personalised recommendations